Alper Bilgic1, Aditya Sudhalkar, Jesus H Gonzalez-Cortes, Francesc March de Ribot, Rohit Yogi, Laurent Kodjikian, Thibaud Mathis. 1. Alphavision Augenarztpraxis, Bremerhaven, Germany Sudhalkar Eye Hospital and Retina Centre, Baroda, India Dept. of Ophthalmology, Dr Jose E. Gonzalez Autonomous University of Nuevo Leon. Universitat Autonoma de Barcelona, Barcelona, Spain ASG Group Of Hospitals, Udaipur, India Service d'Ophtalmologie, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Université Lyon 1, Lyon, France Laboratoire UMR-CNRS 5510 Matéis, Université Lyon 1, Villeurbane, France.
Abstract
PURPOSE: To describe endogenous endophthalmitis in the setting of Covid-19 pneumonia. METHODS: Patients recovering from Covid-19 pneumonia who presented to our department with any or all of the following complaints: pain, watering, redness and decreased vision were identified. All relevant data were collected for analysis. RESULTS: Three patients with endogenous endophthalmitis were identified. All patients had been treated for Covid-19 pneumonia and had received Remdesivir and systemic steroids therefor; 2/3 received tocilizumab. All patients received vitreous biopsy, vitrectomy and intraocular antibiotic injection. Patient 1 demonstrated K.pneumoniae in blood culture, K.pneumoniae and E.coli in urine culture, and K.pneumoniae in vitreous fluid, while patients 2 and 3 demonstrated S.maltophilia and Methicillin Resistant S.Aureus in the blood and nasopharyngeal culture respectively. Correspondingly, the same organism was cultured from vitreous in patients 2 and 3. The visual acuity at last follow up in patients 1-3 was 20/100, 20/80 and 20/40 respectively. The probable source of infection was identified in each as renal calculi, dental caries and the pharynx respectively. Real time polymerase chain reaction demonstrated the presence of SARS CoV-2 in the vitreous fluid of patient 1. CONCLUSION: We report good outcomes of early intervention for endogenous endophthalmitis in the setting of Covid-19 infection. We also document the presence of SARS-CoV-2 in vitreous.
PURPOSE: To describe endogenous endophthalmitis in the setting of Covid-19 pneumonia. METHODS:Patients recovering from Covid-19 pneumonia who presented to our department with any or all of the following complaints: pain, watering, redness and decreased vision were identified. All relevant data were collected for analysis. RESULTS: Three patients with endogenous endophthalmitis were identified. All patients had been treated for Covid-19 pneumonia and had received Remdesivir and systemic steroids therefor; 2/3 received tocilizumab. All patients received vitreous biopsy, vitrectomy and intraocular antibiotic injection. Patient 1 demonstrated K.pneumoniae in blood culture, K.pneumoniae and E.coli in urine culture, and K.pneumoniae in vitreous fluid, while patients 2 and 3 demonstrated S.maltophilia and Methicillin Resistant S.Aureus in the blood and nasopharyngeal culture respectively. Correspondingly, the same organism was cultured from vitreous in patients 2 and 3. The visual acuity at last follow up in patients 1-3 was 20/100, 20/80 and 20/40 respectively. The probable source of infection was identified in each as renal calculi, dental caries and the pharynx respectively. Real time polymerase chain reaction demonstrated the presence of SARS CoV-2 in the vitreous fluid of patient 1. CONCLUSION: We report good outcomes of early intervention for endogenous endophthalmitis in the setting of Covid-19infection. We also document the presence of SARS-CoV-2 in vitreous.
Authors: Mohammad Javad Zibaeenezhad; Alireza Moaref; Firoozeh Abtahi; Mohsen Moghadami; Mohammad Karim Johari; Ali Ardekani; Mohammad Keshavarz Journal: Clin Case Rep Date: 2022-05-12
Authors: Timothy P H Lin; Chung-Nga Ko; Ke Zheng; Kenny H W Lai; Raymond L M Wong; Allie Lee; Shaochong Zhang; Suber S Huang; Kelvin H Wan; Dennis S C Lam Journal: Asia Pac J Ophthalmol (Phila) Date: 2021-11-24
Authors: Jacek Baj; Alicja Forma; Barbara Teresińska; Magdalena Tyczyńska; Julita Zembala; Jacek Januszewski; Jolanta Flieger; Grzegorz Buszewicz; Grzegorz Teresiński Journal: J Clin Med Date: 2022-06-13 Impact factor: 4.964